Rinucumab

Rinucumab
Monoclonal antibody
Type?
SourceHuman
Targetplatelet-derived growth factor receptor beta
Clinical data
Other namesREGN2176
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6472H9974N1710O2022S38
Molar mass145309.21 g·mol−1

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.

This drug was developed by Regeneron Pharmaceuticals, Inc.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.